跳至主要内容
临床试验/NCT07053722
NCT07053722尚未招募不适用

Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy

Peking University First Hospital0 个研究点目标入组 30 人开始时间: 2025年6月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
30
主要终点
DFS

研究概览

简要总结

The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC. The main question it aims to answer is: Does this treatment model improve long - term outcomes, including survival, local control, distant metastasis, and bladder preservation rates? Participants who received neoadjuvant therapy and underwent TMT for bladder preservation will be observed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histopathologically confirmed bladder cancer (T2-T4aN0-2M0, 8th edition AJCC staging).
  • Underwent bladder - sparing TMT following neoadjuvant therapy (ADC, immunotherapy, or chemotherapy).
  • Aged ≥18 years. Signed an informed consent form. Good general condition with ECOG performance status of 0-
  • Adequate organ function for chemoradiotherapy: (1) Hematology: Absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L, hemoglobin ≥90 g/L. (2) Liver function: Total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN (≤5×ULN if hepatic metastasis is present). (3) Renal function: Creatinine clearance ≥30 mL/min (via Cockcroft-Gault formula).

排除标准

  • Distant metastasis (M1). Other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ).
  • Severe cardiovascular disease (uncontrolled heart failure, unstable angina, myocardial infarction, etc.).
  • Severe hepatic/renal dysfunction intolerance to chemoradiotherapy. Mental illness/cognitive impairment unable to comply with the study. Allergy to chemoradiotherapy drugs. Pregnant or breastfeeding women. Previous pelvic radiotherapy.

结局指标

主要结局

DFS

时间窗: 5 years

OS

时间窗: 5 years

BI - EFS

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shangbin QIN

Doctor

Peking University First Hospital

相似试验

Observational Clinical Study of Patients With Muscle... | 临床试验